Advisory - Several children's strawberry-flavoured acetaminophen syrups recalled because of defective child-resistant safety caps on the bottles
OTTAWA, Nov. 14, 2018 /CNW/ -
Issue Laboratoire Riva Inc. and Laboratoires Trianon Inc. are voluntarily recalling several over-the-counter children's strawberry-flavoured acetaminophen syrups labeled as Biomedic, Option+, or Laboratoires Trianon Inc. The products, which are used for pain and fever relief, are being recalled because the child-resistant safety cap may be defective.
A defective cap could allow a child to accidentally ingest the product, which would pose a significant health concern. Accidental ingestion can result in acetaminophen overdose and serious health consequences, including liver damage in extreme cases. Early signs of overdose include nausea, vomiting, lethargy and sweating. Liver damage may result in liver failure or death. Abdominal pain may be the first sign of liver damage and may not be apparent for 24 to 48 hours.
This issue is related to product packaging and not the safety or effectiveness of the drug in the bottles. The products were distributed at major pharmacies across Canada.
Who is affected
Consumers who have bought the affected products listed in the table below
Return affected product to the place of purchase for a refund.
Call your local poison control centre immediately if you think your child may have taken too much acetaminophen. Consult your health care professional if your child has used these products and has health concerns.
Contact Urszula Wiatrowska, Pharmacovigilance Specialist at Laboratoire Riva and Laboratoires Trianon Inc., if you have questions about the recall. Email [email protected], or call toll-free at 1-800-363-7988, extension 236.
Store medications out of reach and sight of children.
What Health Canada is doing Health Canada is monitoring the recalls. Should additional safety concerns be identified related to this issue, Health Canada will take appropriate action and inform Canadians as necessary.
Stay connected with Health Canada and receive the latest advisories and product recalls.
StateHouse Holdings Inc. ("StateHouse" or the "Company") , a California-focused, vertically integrated cannabis company, today announced further to its press release dated April 15, 2024, that the Ontario Securities Commission (the "OSC") has denied...
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31,...
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:
On Thursday, the FDA posted a safety communication to inform the public and healthcare providers that the agency has required and...
Unifor expects to achieve the wage increases and benefit improvements awarded to Ontario OCHU-CUPE and SEIU Healthcare members by Arbitrator William Kaplan in a recent decision....
Acadia Pharmaceuticals Inc. today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common...
Calidi Biotherapeutics, Inc. , a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the closing of its previously announced public offering of 15,197,500 shares of common stock (or pre-funded...